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INTRODUCTION
Anterior uveitis (AU) is the most common form of intraoc-
ular inflammation, and accounts for 50% to 92% of total
uveitis cases in most western countries and 28% to 50% of
all uveitis cases in some of the Asian countries, such as Korea,
Japan, and India (1). As the second most common AU next
to idiopathic HLA-B27 negative AU, HLA-B27 positive AU
accounts for 18% to 32% of all AU cases in western countries
and 6% to 13% of all AU cases in Asia (2). In a previous hos-
pital-based study, AU accounted for approximately 28.1%
of all uveitis cases in Korea (3), and 35% to 47% of AU pa-
tients were positive for HLA-B27 in other studies (4, 5).
HLA-B27 positive AU is distinguishable from its HLA-
B27 negative counterpart and is characterized by early onset,
male preponderance, frequent association with systemic dis-
eases, and a high tendency for recurrence (2, 6). There have
been many comparative studies on the prognosis of HLA-B27
positive and negative AU with conflicting results. Some stud-
ies revealed more favorable outcomes for HLA-B27 positive
AU (7, 8), whereas others reported the opposite (9). In addi-
tion, an equal ocular outcome was observed for both HLA-
B27 positive and negative groups in some studies (10-14).
This study was performed to assess the clinical features and
prognosis of HLA-B27 positive AU compared with HLA-
B27 negative AU in a Korean population. In addition, the
effects of associated systemic disease on HLA-B27 positive
AU were also evaluated.
MATERIALS AND METHODS
This study was a retrospective case-controlled study, and
was approved by Institutional Review Board. The medical
records of all patients with AU seen at the uveitis service of
a university hospital in Korea, between January 1996 and
December 2006 were reviewed throughout patients’ entire
follow-up and those who were tested for the presence of the
HLA-B27 allele were included in this study. HLA-B27 typ-
ing was conducted for patients who agreed to perform the test
after receiving information on the diagnostic, therapeutic,
and prognostic significance of HLA-B27 typing. Exclusion
criteria were patients with an associated primary uveitic con-
dition (e.g., Fuchs’ heterochromic cyclitis or infectious uveitis)
and other systemic and/or ocular diseases that are likely to be
associated with ocular complications and visual prognosis inde-
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pendent of the HLA-B27 antigen (e.g., sarcoidosis, Behcet’s
disease, proliferative diabetic retinopathy, retinal vascular ob-
struction, glaucoma not associated with the present AU). Pa-
tients were divided into two groups: those with a negative
HLA-B27 haplotype who presented with idiopathic AU (group
I) and those who were positive for HLA-B27 (group II). Group
II was further divided into two subgroups; patients with a
systemic disease association (e.g., spondyloarthropathy, inflam-
matory bowel disease) (group IIA) and those who had no evi-
dence of systemic disease association (group IIB).
A detailed medical and ophthalmologic history taking, a
complete blood count, liver function tests, blood urea nitro-
gen, serum creatinine, urinalysis, C-reactive protein, anti-strep-
tolysin O, rheumatoid factor, antinuclear antibody, serologic
tests for toxoplasmosis and syphilis, human immunodeficien-
cy virus test, hepatitis B and C tests, angiotensin-converting
enzyme, and chest radiography were performed at the initial
visit for each patient. In patients with previous episodes of
uveitis, the total number of previous attacks and the age at
their first episode were recorded during patient interviews.
The ophthalmological examination performed at every visit
included best-corrected visual acuity (BCVA), slit-lamp biomi-
croscopy, tonometry, and indirect ophthalmoscopy; and sys-
temic disease association was documented in every possible
case. Fluorescein angiography, optical coherence tomogra-
phy, and anterior segment and fundus photography were per-
formed when indicated. Patients without prior rheumato-
logic evaluation at the time of inclusion were referred to a
rheumatologist, and medical records were reviewed for pati-
ents with a previous rheumatologic follow-up.
The characteristics of the uveitis were analyzed according
to the definitions of the Standardization of Uveitis Nomen-
clature (SUN) Working Group (15). AU was defined by ante-
rior chamber cell grade of ≥1+ (graded according to the SUN
Working Group grading scheme) of acute onset.
All patients were treated according to the degree of intraoc-
ular inflammation (cells in the anterior chamber or vitreous
cavity or both) using a stepladder steroid-sparing therapeu-
tic algorithm (16). Most patients initially were treated with
topical corticosteroids. Periocular corticosteroids were used
for severe, recurrent, or chronic episodes, for cystoid macu-
lar edema, and for patients in whom systemic corticosteroids
were contraindicated. Long-term topical nonsteroidal anti-
inflammatory drugs (NSAIDs) were sometimes used to pre-
vent relapse of inflammation in cases of active inflammation
recurrence with attempted topical steroid withdrawal. Short
course systemic corticosteroids were given if the inflamma-
tion could not be controlled with previous therapy. Systemic
immunosuppressive agents were used in patients in whom
previous therapeutic strategies had failed. Ophthalmic fol-
low-up was dependent on symptoms.
The distribution of counts was analyzed using chi-square
test and Fisher’s exact test where appropriate for the determi-
nation of statistical significance. For the comparison of mean
values, independent t-test and Wilcoxon’s rank sum test were
used where appropriate. SPSS version 11.0 for Windows (SPSS
Inc., Chicago, IL, U.S.A.) was used, and the results were con-
sidered to be significant at Pvalues of less than 0.05.
RESULTS
Eighty-two Korean patients were included in the present
study, and 27 patients (40 eyes) tested HLA-B27 negative
and suffered from AU of unknown etiology (group I). Fifty-
five HLA-B27 positive patients (88 eyes) (group II) were fur-
ther divided into 29 (52.7%) patients (47 eyes) with systemic
disease association (group IIA) and 26 (47.3%) patients (41
eyes) with no systemic disease association (group IIB). The
median follow-up period for all 82 patients was 36.5 months
(interquartile range, 16.0-75.3 months).
Clinical features
The general characteristics of the four study groups are
summarized in Table 1. There was no obvious male or female
predominance in group I (male:female ratio, 1.08:1), where-
as there were approximately three times more male patients
in group II (male:female ratio, 2.9:1), and this difference bet-
ween groups I and II was statistically significant (P=0.040).
Among the two subgroups of the HLA-B27 positive group,
group IIA (male:female ratio, 8.7:1) had a significantly high-
*P value for difference between groups I and II <0.05; 
� P value for difference between groups IIA and IIB <0.05; 
� Values are described as median
(interquartile range); 
�
Values are described as mean±standard deviation; 
‖Unilateral alternating or bilateral simultaneous.
General characteristics
Group I
HLA-B27(-)
idiopathic
Group II
HLA-B27(+)
total
Group IIA
HLA-B27(+)
systemic disease
Group IIB
HLA-B27(+)
no systemic disease
Follow-up period (months)
� 27 (14-64) 38 (17-85) 32 (12.5-48.5)
� 48.5 (30.5-104)
�
Number of subjects (eyes) 27 (40) 55 (88) 29 (47) 26 (41)
Male:Female 14:13* 41:14* 26:3
� 15:11
�
Age of onset (yr) (range)
� 34.9±16.1 (10-65) 35.3±12.5 (12-68) 32.0±12.7 (12-68)
� 38.8±11.4 (16-61)
�
Bilateral
‖ 48.1% (13/27) 60.0% (33/55) 62.1% (18/29) 57.7% (15/26)
Table 1. General characteristics of HLA-B27 positive and negative anterior uveitis724 S.C. Park and D.-I. Ham
er male:female ratio than did group IIB (male:female ratio,
1.4:1) (P=0.007). AU started in the 30s on average in all 4
study groups. The age of onset of AU was statistically simi-
lar between HLA-B27 negative and positive AU groups (P=
0.919), and the age of onset of group IIA was significantly
younger than that of group IIB (P=0.015).
HLA-B27 positive AU showed more severe anterior cham-
ber inflammation than its HLA-B27 negative counterpart.
The mean grade of anterior chamber cells and the rate of hy-
popyon formation were significantly higher in the eyes of
group II than in those of group I (P=0.006 and 0.034, respec-
tively); hypopyon occurred almost exclusively in HLA-B27
positive eyes (Table 2). The proportions of anterior chamber
cells of grade 3 or more and grade 4 were significantly higher
in the eyes of the HLA-B27 positive group than in the eyes
of the HLA-B27 negative group (P=0.001 and 0.041, respec-
tively) (Fig. 1). In the analysis of the anterior chamber inflam-
mation between the eyes of groups IIA and IIB, there were no
statistically significant differences (P>0.05, Table 2, Fig. 1).
A clear distinction of the visual outcome during the active
inflammatory stage was observed between HLA-B27 nega-
tive and positive groups (Table 2). Approximately four out
of five HLA-B27 negative AU eyes (81.5%) had BCVA of
20/40 or better during the active inflammatory stage, where-
as approximately two out of three HLA-B27 positive AU eyes
(65.7%) had BCVA worse than 20/40. In addition, about
one out of three HLA-B27 positive AU eyes (32.8%) had
BCVA of 20/200 or worse, whereas less than one out of ten
HLA-B27 negative AU eyes (7.4%) had BCVA of 20/200
or worse (P=0.011). The proportion of eyes with BCVA of
20/40 or better was significantly larger in group I than in
group II (P<0.001), and the proportion of eyes with BCVA
between 20/40 and 20/100 and the proportion of eyes with
BCVA between 20/100 and 20/400 were significantly larg-
er in group II than in group I (P=0.031 and 0.030, respec-
tively). In the analysis of the worst BCVA between the eyes
*P value for difference between groups I and II <0.05; 
�
The eyes whose data in active inflammatory stage were not available (e.g. patients referred
after long-term treatment) were excluded in the analysis; 
�
Data from the eyes with ocular conditions that could possibly affect the BCVA independent-
ly of AU (e.g. pre-existing cataract) were excluded in the analysis; 
�
Values are described as mean±standard deviation.
BCVA, best-corrected visual acuity; LP, light perception; CF, counting fingers; NLP, no light perception.
General characteristics
�
Group I
HLA-B27(-)
idiopathic
Group II
HLA-B27(+)
total
Group IIA
HLA-B27(+)
systemic disease
Group IIB
HLA-B27(+)
no systemic disease
Anterior chamber inflammation
�
Cells
� 2.66±1.04* 3.25±0.91* 3.42±0.81 3.07±1.02
Fibrin 20.7% (6/29) 26.8% (19/71) 27.8% (10/36) 25.7% (9/35)
Hypopyon 3.5% (1/29)* 21.1% (15/71)* 19.4% (7/36) 22.9% (8/35)
Keratic precipitate 48.8% (14/29) 40.8% (29/71) 38.9% (14/36) 42.9% (15/35)
Worst BCVA during active stage
�
20/40≤≤ 20/20 81.5% (22/27)* 34.3% (23/67)* 29.4% (10/34) 39.4% (13/33)
20/100≤ <20/40 11.1% (3/27)* 32.8% (22/67)* 38.2% (13/34) 27.3% (9/33)
20/400≤ <20/100 0% (0/27)* 16.4% (11/67)* 17.6% (6/34) 15.2% (5/33)
LP≤≤ CF 7.4% (2/27) 16.4% (11/67) 14.7% (5/34) 18.2% (6/33)
NLP 0% (0/27) 0% (0/67) 0% (0/34) 0% (0/33)
Table 2. Clinical characteristics during active inflammatory stage of HLA-B27 positive and negative anterior uveitis (AU)
Fig. 1. Anterior chamber cells during the active inflammatory stage. (A) HLA-B27 negative vs. positive anterior uveitis (AU). The proportions
of grade 3 or more and grade 4 were significantly higher in the HLA-B27 positive eyes than in the HLA-B27 negative eyes. (B) HLA-B27
positive AU with vs. without systemic disease association. Associated systemic disease made no significant difference in the anterior cham-
ber cells in the HLA-B27 positive AU patients.
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of groups IIA and IIB, there were no significant differences
in all ranges of visual acuity (P>0.05, Table 2).
Systemic or periocular steroids were required in significantly
more patients in the HLA-B27 positive group (approximate-
ly 4 out of 5 patients) than in the HLA-B27 negative group
(approximately 1 out of 2 patients) (P=0.015, Table 3). Fur-
ther analysis revealed that both oral and periocular steroids
were used more frequently in HLA-B27 positive patients than
in HLA-B27 negative patients (P=0.032 and 0.021, respec-
tively). The presence of a systemic disease association made
no significant difference in the medical treatment of AU in
the HLA-B27 positive group (P>0.05, Table 3).
The disease duration and course including the frequency
of uveitis attack are summarized in Table 4. Approximately
9 out of 10 study patients (92.6% of group I and 92.7% of
group II) had limited (3 months or less) AU with a mean dura-
tion of about one month, and approximately 9 out of 10 study
patients had repeated episodes of AU (85.2% of group I and
90.9% of group II). There were no significant differences in
the proportions of limited/persistent, single/repeated, and
chronic cases and in the duration of an episode between HLA-
B27 negative and positive AU groups (P>0.05), but AU oc-
curred significantly more often in patients with the HLA-
B27 haplotype (2.07 attacks/year) than in those without the
HLA-B27 haplotype (1.47 attacks/year) (P=0.007). No sig-
nificant differences in the disease duration and course were
observed between HLA-B27 positive patients with or with-
out associated systemic disease (P>0.05, Table 4).
Ocular complications and final visual outcomes
The ocular complications and final visual outcomes in the
four study groups are described in Table 5. The most common
ocular complication observed in both HLA-B27 negative and
positive groups was increased intraocular pressure (IOP) (40.0%
and 27.3%, respectively). However, there were no significant
differences in the proportions of eyes with cataract, cystoid
macular edema, increased IOP, secondary glaucoma, or pos-
terior synechia between HLA-B27 negative and positive AU
groups and between HLA-B27 positive AU groups with or
without systemic disease (P>0.05).
Group I and II (and group IIA and IIB also) showed simi-
lar good final visual outcomes (Table 5). Over 90% of eyes
in each study group had final BCVA of 20/40 or better, and
*P value for difference between groups I and II <0.05.
NSAID, non-steroidal anti-inflammatory drug.
Therapeutic agents
Group I
HLA-B27(-)
idiopathic (n=27)
Group II
HLA-B27(+)
total (n=55)
Group IIA
HLA-B27(+)
systemic disease
(n=29)
Group IIB
HLA-B27(+)
no systemic disease
(n=26)
Topical steroids 100% (27/27) 100% (55/55) 100% (29/29) 100% (26/26)
Topical NSAIDs 11.1% (3/27) 16.4% (9/55) 13.8% (4/29) 19.2% (5/26)
Systemic or periocular steroids 51.9% (14/27)* 78.2% (43/55)* 79.3% (23/29) 76.9% (20/26)
Oral steroids 44.4% (12/27)* 69.1% (38/55)* 69.0% (20/29) 69.2% (18/26)
High-dose intravenous steroids 3.7% (1/27) 3.6% (2/55) 3.4% (1/29) 3.8% (1/26)
Periocular steroids 14.8% (4/27)* 40.0% (22/55)* 34.5% (10/29) 46.1% (12/26)
Systemic immunosuppressive agents  7.4% (2/27) 5.5% (3/55) 6.9% (2/29) 3.8% (1/26)
(methotrexate or cyclosporin)
Table 3. Medical treatment of HLA-B27 positive and negative anterior uveitis
*P value for difference between groups I and II <0.05; 
�
The characteristics of uveitis were analyzed according to definitions of the Standardization of
Uveitis Nomenclature (SUN) Working Group. Limited: ≤3 months duration, persistent: >3 months duration, Repeated: episodes separated by peri-
ods of inactivity (grade 0 cells in the anterior chamber) without treatment irrespective of the interval between episodes. Chronic: relapsing episodes in
<3 months after discontinuing treatment; 
�
Values are described median (interquartile range).
Disease duration/
Recurrence
�
Group I
HLA-B27(-)
idiopathic (n=27)
Group II
HLA-B27(+)
total (n=55)
Group IIA
HLA-B27(+)
systemic disease
(n=29)
Group IIB
HLA-B27(+)
no systemic disease
(n=26)
Limited:Persistent 92.6%:7.4% (25:2) 92.7%:7.3% (51:4) 93.1%:6.9% (27:2) 92.3%:7.7% (24:2)
Duration of an episode (days)
� 33 (14-68) 35 (26-53) 34 (20-53) 37.5 (28-50)
Single:Repeated 14.8%:85.2% (4:23) 9.1%:90.9% (5:50) 13.8%:86.2% (4:25) 3.8%:96.2% (1:25)
Chronic 11.1% (3/27) 14.5% (8/55) 17.2% (5/29) 11.5% (3/26)
Attack per patient per year
� 1.47 (0.84-3.00)* 2.07 (1.50-3.33)* 2.07 (1.48-4.26) 2.05 (1.53-3.26)
Table 4. Disease duration and recurrence of HLA-B27 positive and negative anterior uveitis726 S.C. Park and D.-I. Ham
86.1% (31/36), 82.8% (72/87), 89.1% (41/46), and 75.6%
(31/41) of the eyes in groups I, II, IIA, and IIB, respectively,
had final BCVA of 20/20. There were no significant differ-
ences in the mean logMAR (logarithm of the minimum angle
of resolution) BCVA between the eyes of groups I and II and
between the eyes of groups IIA and IIB (light perception was
assigned the logMAR equivalent 2.70) (P=0.687 and 0.161,
respectively). Fig. 2 shows the Kaplan-Meier survival curves
of eyes with a potential BCVA of ≥20/40 and ≥20/32 in
HLA-B27 negative versus positive AU patients, and there
was no significant difference between HLA-B27 negative and
positive AU patients (P=0.8118 and 0.4286, respectively; by
log rank test). There was only one legally blind eye (BCVA of
20/200 or worse) with final BCVA of light perception among
all study eyes. This patient, who had ankylosing spondylitis
and the HLA-B27 haplotype, had his first AU occurrence
in the left eye when he was 24 yr old, and he had secondary
chronic angle closure glaucoma after recurrent AU episodes.
Glaucoma implant surgery and a penetrating keratoplasty
were performed in his left eye, but his BCVA eventually de-
creased to light perception.
DISCUSSION
Many studies have been reported on the clinical features
and prognosis of HLA-B27 positive AU (7-14, 17, 18). How-
ever, the ocular complications and visual outcomes of HLA-
*Data from the eyes with ocular conditions that could possibly affect the BCVA independently of AU (e.g. pre-existing cataract) were excluded in the
analysis; 
�
BCVA 20/200 or worse.
IOP, intraocular pressure; LP, light perception; CF, counting fingers; NLP, no light perception.
Group I
HLA-B27(-)
idiopathic
Parameters
Group II
HLA-B27(+)
total
Group IIA
HLA-B27(+)
systemic disease
Group IIB
HLA-B27(+)
no systemic disease
Ocular complications
Cataract formation (≥grade 2) 15.0% (6/40) 5.7% (5/88) 6.4% (3/47) 4.9% (2/41)
Cystoid macular edema 2.5% (1/40) 9.1% (8/88) 6.4% (3/47) 12.2% (5/41)
IOP (>21 mmHg) 40.0% (16/40) 27.3% (24/88) 19.1% (9/47) 36.6% (15/41)
Secondary glaucoma 10.0% (4/40) 2.3% (2/88) 2.1% (1/47) 2.4% (1/41)
Posterior synechia 12.5% (5/40) 22.7% (20/88) 21.3% (10/47) 24.4% (10/41)
Final BCVA in remission
�
20/40≤≤ 20/20 97.2% (35/36) 95.4% (83/87) 93.5% (43/46) 97.6% (40/41)
20/100≤ <20/40 2.8% (1/36) 3.4% (3/87) 4.3% (2/46) 2.4% (1/41)
20/400≤ <20/100 0% (0/36) 0% (0/87) 0% (0/46) 0% (0/41)
LP≤≤ CF 0% (0/36) 1.1% (1/87) 2.2% (1/46) 0% (0/41)
NLP 0% (0/36) 0% (0/87) 0% (0/46) 0% (0/41)
Number of legally blind eyes
� 0% (0/36) 1.1% (1/87) 2.2% (1/46) 0% (0/41)
Table 5. Ocular complications and final best-corrected visual acuity (BCVA) in remission of HLA-B27 positive and negative anterior
uveitis (AU)
Fig. 2. Kaplan-Meier curves showing cumulative survival of eyes with a potential best-corrected visual acuity of (A) ≥20/40 and (B) ≥20/32
in HLA-B27 negative vs. positive anterior uveitis patients. P values were calculated by log rank test.
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B27 positive AU compared to HLA-B27 negative AU con-
tinue to be controversial. As mentioned in an earlier report
(2), some of the conflicting findings may result from differ-
ences in the follow-up period and in the inclusion and diag-
nostic criteria used in various studies. Evaluation of the effect
of the HLA-B27 haplotype on the ocular and visual progno-
sis of AU in patients with HLA-B27 positive AU compared
to the HLA-B27 negative AU group is complicated by the
heterogeneity of the HLA-B27 negative AU group (2). That
is, inclusion of distinct uveitic entities, which are likely to
be associated with ocular complications and visual progno-
sis independent of the HLA-B27 antigen (such as sarcoido-
sis and Behcet’s disease), may make it difficult to evaluate the
effect of the HLA-B27 antigen on the complications and out-
comes of AU. In the present study, only idiopathic cases of
HLA-B27 negative AU were included to minimize potential
confounding factors, similarly to a previous report (9). In addi-
tion, the effects of associated systemic disease on HLA-B27
positive AU were also evaluated by further dividing the HLA-
B27 positive AU group into two subgroups: patients with a
systemic disease association and those who had no evidence
of systemic disease association.
The clinical features of HLA-B27 positive AU in this study
are generally similar to those in previously published reports
from other Western (7-12, 14, 17) and Asian countries (13,
18). The common characteristics include an increased frequen-
cy among male patients and a significant association with
HLA-B27-related systemic disease as well as a significant cel-
lular reaction in the anterior chamber with hypopyon requir-
ing more aggressive treatment and with a higher frequency
of recurrent attacks. In terms of the ocular complications and
final visual outcomes, for which there have been conflicting
results reported, the present study revealed no significant dif-
ference in the overall outcome between the HLA-B27 nega-
tive and positive groups. A previous study with less favorable
outcomes for HLA-B27 positive AU was conducted on pa-
tients seen between 1982 and 1993 (9). Therapeutic strate-
gies for HLA-B27 positive AU have somewhat changed, and
more intensive treatment is now given to HLA-B27 positive
AU patients. This more aggressive treatment for HLA-B27
positive AU may explain the similar overall outcomes bet-
ween HLA-B27 negative and positive groups in the current
study, which reviewed AU patients treated between 1996
and 2006.
In terms of the effect of the systemic disease association on
the HLA-B27 positive AU, our study showed no significant
difference in the ocular complications and final visual out-
comes between HLA-B27 positive AU patients with systemic
disease (group IIA) and those with no systemic disease (group
IIB). This finding is in accord with the results of earlier reports
(9, 16). One of the earlier reports revealed that the mean recur-
rence rate of inflammation was higher in HLA-B27 positive
patients with systemic disease (3.6 attacks) than in those with
no systemic disease (5.2 attacks) (9). However, another report
showed that there was no significant difference in the mean
frequency of attacks between HLA-B27 positive AU patients
with systemic disease (0.8 attacks/year) and those with no
systemic disease (0.7 attacks/year) (16), and our study results
were consistent with the latter one with the median frequen-
cy of attacks of 2.07 and 2.05 attacks/year in groups IIA and
IIB, respectively.
Previous reports on the clinical characteristics of HLA-B27
positive AU in Asian countries are scarce, and no compara-
tive study on the clinical characteristics of HLA-B27 posi-
tive and negative AUs in Korean populations has been report-
ed in the international ophthalmic literature. In an earlier
report (18), Chinese AU patients with the HLA-B27 haplo-
type had a generally good visual prognosis with 90.3% of the
affected eyes having a visual acuity better than 20/40, although
66.8% of patients had recurrent uveitis episodes and 31.4%
and 14.3% of the affected eyes had posterior synechiae and
cataract, respectively. In another report from Thailand (13),
clinical features of HLA-B27 positive and negative acute AU
were similar to those reported in Western countries with no
significant differences in the visual outcomes between HLA-
B27 positive and negative groups. In contrast to most prior
Western reports that noted a larger proportion of increased
IOP in the HLA-B27 positive group than in the HLA-B27
negative group (9, 12), however, the proportion of cases with
increased IOP was significantly higher in HLA-B27 nega-
tive group than in HLA-B27 positive group. In the current
study, an increased IOP (>21 mmHg) and secondary glau-
coma were more common in the HLA-B27 negative patients
(40.0% and 10.0%, respectively) than in the HLA-B27 pos-
itive patients (27.3% and 2.3%, respectively), although there
were no statistically significant differences (P=0.150 and 0.076,
respectively). The explanation for this finding is unclear. The
increased IOP may be attributed to the AU itself and/or the
steroid treatment for AU. In addition, the etiology of HLA-
B27 negative AU in Asia might include more cases of vari-
ous viral infections (often associated with increased IOP) as
suggested in a previous study (13).
Previous studies on the clinical characteristics and prog-
nosis of HLA-B27 positive and/or negative AU in Korean
patients were published in a domestic ophthalmologic jour-
nal (19, 20). Lee et al. (19) recruited 32 AU patients from
462 HLA-B27 positive spondyloarthropathy patients; the
clinical characteristics of HLA-B27 positive AU were simi-
lar to this study except for the prominent unilateral involve-
ment (31/32, 96.8%) and no occurrence of hypopyon (0/32,
0%). However, the follow-up period for the 32 AU patients
was not mentioned and therefore these differences might be
due to a shorter follow-up. Another study by Kim et al. (20)
also demonstrated similar results. However, patients with
posterior uveitis were included (4/27 eyes) making the group
more heterogeneous. A comparative study between HLA-B27
positive and negative AU patients (5) showed more severe
inflammation in the anterior chamber and more aggressive728 S.C. Park and D.-I. Ham
treatment in HLA-B27 positive AU compared to HLA-B27
negative AU, and the final visual outcomes were similar bet-
ween the two groups. However, the number of subjects was
relatively small (16 in HLA-B27 positive group and 18 in
HLA-B27 negative group). The current study analyzed the
largest data set to date available on Korean patients with HLA-
B27 positive and negative AU. In addition, we compared the
subgroups of HLA-B27 positive AU with or without systemic
disease.
The significance of our results may partly be limited by
referral bias as this study was based at a university hospital
(tertiary referral center) with more complicated and severe
cases. Thus, the clinical features of both HLA-B27 negative
and positive AUs would generally have a better prognosis
than is described in this study, as pointed out in a previous
report (2). In addition, our results are also subject to selection
bias because HLA-B27 typing was conducted only for pati-
ents who agreed to perform the test after receiving informa-
tion on the diagnostic, therapeutic, and prognostic signifi-
cance of HLA-B27 typing.
In conclusion, the ocular and visual outcomes of HLA-B27
positive AU patients in Korea are generally good and show no
significant difference from those of HLA-B27 negative AU.
The more aggressive treatment for significantly severer and
recurrent anterior chamber inflammation in HLA-B27 posi-
tive AU is a feasible explanation for these findings. No sig-
nificant differences in clinical characteristics, medical treat-
ment, disease duration and course, and final ocular and visu-
al outcomes were observed between the HLA-B27 positive
AUs with or without associated systemic disease.
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